Alpha Cognition Inc.
Alpha Cognition is a biopharmaceutical company developing treatments for neurodegenerative diseases, including Alzheimer’s disease. Its main commercial product is ZUNVEYL, a delayed-release oral tablet approved for mild-to-moderate dementia of the Alzheimer’s type in adults and launched in the United States on March 19, 2025. The company markets it through a specialty sales force focused on long-term care physicians and nursing homes, and seeks payer coverage and pharmacy benefit manager agreements. It also licenses ZUNVEYL for development, manufacturing and commercialization in Asia excluding Japan, Australia and New Zealand, in return for payments and royalties. Alpha Cognition’s other programs include pre-clinical work on ZUNVEYL combinations and formulations, and ALPHA-1062 for mild traumatic brain injury and acute pancreatitis. The company contracts with manufacturers to produce ZUNVEYL’s active ingredient and oral tablets. Alpha Cognition is headquartered in Grapevine, Texas.
No enriched coverage for $ACOG in the last 7 days.
Opaleye Management Inc. purchased 32,090 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.28 ($8.23–$8.33, $0.27M total) across 2 trades over 2026-10-22 to 2026-10-23.
Opaleye Management Inc. purchased 36,940 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.35 ($8.23–$8.43, $0.31M total) across 2 trades over 2026-10-15 to 2026-10-16.
Alpha Cognition Inc. (ACOG) announced the U.S. Patent and Trademark Office published its patent application for manufacturing benzgalantamine, the active ingredient in ZUNVEYL, a drug for Alzheimer’s disease. The application covers manufacturing efficiency, product quality, and scalability. The company noted that patent applications may not result in issued patents and that issued patents may be challenged. ACOG is a biopharmaceutical company focused on neurodegenerative disease treatments.
Recent ACOG coverage spans insider activity, corporate actions and technology.
In the last 30 days, ACOG insiders filed 4 SEC Form 4 transactions — 4 purchases ($574K) and no sales. The most active reporter was Opaleye Management Inc. with 4 filings.
The insider purchase adds modest buying pressure on ACOG.
The insider purchase may signal confidence in Alpha Cognition, creating modest buying pressure.
The new patent filing may improve manufacturing efficiency and protect the ZUNVEYL product, potentially supporting the stock.
The grant modestly increases share dilution and may exert slight downward pressure on the stock.
Insider purchase adds modest buying pressure.
AlphAI scores every news story that mentions ACOG with an AI model for sentiment and relevance, and aggregates insider trades from Alpha Cognition Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Opaleye Management Inc. purchased 32,090 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.28 ($8.23–$8.33, $0.27M total) across 2 trades over 2026-10-22 to 2026-10-23.
Opaleye Management Inc. purchased 36,940 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.35 ($8.23–$8.43, $0.31M total) across 2 trades over 2026-10-15 to 2026-10-16.
Alpha Cognition Inc. (ACOG) announced the U.S. Patent and Trademark Office published its patent application for manufacturing benzgalantamine, the active ingredient in ZUNVEYL, a drug for Alzheimer’s disease. The application covers manufacturing efficiency, product quality, and scalability. The company noted that patent applications may not result in issued patents and that issued patents may be challenged. ACOG is a biopharmaceutical company focused on neurodegenerative disease treatments.
Alpha Cognition (ACOG) granted 6,000 stock options to a new non-executive employee. The options have an exercise price of $8.70, vest over three years, and comply with Nasdaq Rule 5635(c)(4). The company develops treatments for neurodegenerative diseases, including Alzheimer’s and mTBI.
Opaleye Management Inc. purchased 19,050 indirectly-held shares of Alpha Cognition Inc. (ACOG) at $8.69 ($0.17M total) on 2026-10-01.
Opaleye Management Inc. purchased 31,763 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.53 ($8.47–$8.57, $0.27M total) across 2 trades over 2026-09-24 to 2026-09-25.
Opaleye Management Inc. purchased 123,918 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $8.57 ($8.40–$8.70, $1.06M total) across 4 trades over 2026-09-14 to 2026-09-16.
Alpha Cognition (ACOG) granted 20,000 stock options to a new employee, exercisable at $9.27 per share, vesting over three years. The options comply with Nasdaq Rule 5635(c)(4) and are part of the company's 2026 Inducement Grant Plan. ACOG focuses on neurodegenerative disease treatments, including ZUNVEYL for Alzheimer's and ALPHA-1062 for Alzheimer's and mTBI.
Wills Robert James purchased 10,000 shares of Alpha Cognition Inc. (ACOG) at $9.62 on 2026-08-21.
B.Riley initiated coverage on Alpha Cognition (NASDAQ:ACOG) with a buy rating and $21 price target, citing strong revenue growth and high gross margins. The company reported $6M in Q2 2026 revenue, up 71% sequentially, driven by its Alzheimer's drug ZUNVEYL. Analysts highlight commercial momentum despite challenges in payer expansion.
